Central to this discovery is the identification of the RNA methyltransferase TRMT10C as a key mediator of tumor growth in HCC. This enzyme catalyzes methylation modifications on specific RNA molecules, influencing gene expression patterns vital for cancer cell function. The investigative team demonstrated that disulfiram acts as a copper ionophore, facilitating the intracellular influx of copper ions, which in turn downregulates TRMT10C expression. The suppression of TRMT10C induces a cascade of epitranscriptomic changes, notably diminishing methylation on the messenger RNA (mRNA) of the transcription factor c-FOS. This decrease in methylation stabilizes and increases the expression of c-FOS, a crucial regulatory protein with tumor-suppressor properties in this context.

Elevated levels of c-FOS execute a multi-pronged inhibitory effect on the cancer cell microenvironment. It directly represses the expression of PCSK9, a protein intricately involved in lipid metabolism that frequently becomes aberrantly activated in HCC, contributing to excessive lipid droplet accumulation within tumor cells. This accumulation fosters an environment conducive to rapid cancer cell proliferation and survival. Concurrently, c-FOS impedes CD146, a cell adhesion molecule known for its pivotal role in promoting angiogenesis—the formation of new blood vessels—which tumors require for nutrient supply and metastasis.

The functional consequences of modulating this TRMT10C–c-FOS axis were rigorously validated through a series of in vitro and in vivo experiments. Cultured HCC cell lines treated with disulfiram showed marked reductions in lipid droplets and angiogenic markers, while mouse models exhibited significantly slower tumor growth and diminished vascular structures within tumors. Notably, when disulfiram was combined with thalidomide, an established anti-angiogenic agent, these effects were potentiated, providing evidence for possible synergistic therapeutic regimens targeting multiple facets of tumor biology.

Corroborating the translational relevance of these findings, the research team analyzed clinical data sets from HCC patients. This analysis revealed a stark correlation between patient survival outcomes and the expression profiles of the pathway components. High levels of TRMT10C and PCSK9 were statistically linked to a poor prognosis, reinforcing their oncogenic roles. Conversely, patients exhibiting elevated c-FOS expression experienced comparatively prolonged survival, underscoring the potential prognostic and therapeutic value of modulating this pathway.

From a mechanistic viewpoint, the study highlights a novel epigenetic regulation mode within cancer biology through RNA methylation alterations. RNA methyltransferases like TRMT10C are emerging as critical players in orchestrating gene expression beyond the DNA code, influencing mRNA stability, translation efficiency, and protein synthesis. Disulfiram’s ability to target this enzyme and thereby reprogram the epitranscriptome provides an innovative paradigm for repurposing established drugs with known safety profiles while enhancing therapeutic options for difficult-to-treat malignancies such as HCC.

Beyond its molecular insights, this research underscores the broader clinical imperative of addressing metabolic reprogramming and angiogenesis in cancer treatment. Lipid metabolism abnormalities not only confer growth advantages to tumors but also create metabolic vulnerabilities that can be exploited pharmacologically. Meanwhile, angiogenesis remains a proven therapeutic target, and combining agents that interfere with angiogenic signaling with metabolic disruptors, as demonstrated here, may yield substantial synergistic benefits.

The implications of employing disulfiram in HCC are profound. Traditionally utilized to discourage alcohol consumption by inducing unpleasant physiological responses to ethanol, disulfiram’s repositioning as an anti-cancer agent reflects an exciting trend in oncology: drug repurposing. This approach expedites the translation of existing medications with known pharmacokinetics and toxicity profiles into new therapeutic contexts, reducing development times and costs—a critical advantage in the ongoing battle against cancer.

In summary, the multifaceted investigation elucidated how disulfiram orchestrates the downregulation of TRMT10C, leading to enhanced c-FOS activity that suppresses PCSK9-mediated lipid metabolism and CD146-driven angiogenesis, thereby stymying HCC progression. Such discoveries not only illuminate the intricate biological underpinnings of liver cancer but also furnish a viable therapeutic strategy leveraging RNA epigenetics and metabolic intervention. Moving forward, clinical trials will be essential to evaluate disulfiram’s efficacy and safety as a frontline or adjuvant therapy in HCC patients.

The study, published in the reputable journal Science China Life Sciences, marks a significant milestone in oncology research by integrating molecular biology, cancer metabolism, and epigenetics. It exemplifies how detailed mechanistic studies can unveil drug targets and inform precision medicine strategies aimed at improving outcomes for patients afflicted with aggressive malignancies.

Researchers and clinicians alike should note the potential for combinatory regimens involving disulfiram and anti-angiogenic drugs such as thalidomide to maximize anti-tumor efficacy. Moreover, the identification of biomarkers such as TRMT10C, PCSK9, and c-FOS paves the way for more personalized treatment protocols, wherein patient stratification based on molecular signatures could optimize therapeutic responses.

The findings attest to the transformative power of epitranscriptomic modifications in cancer pathogenesis and treatment, encouraging further exploration of RNA-modifying enzymes as drug targets. These insights also spotlight copper ionophores as a class of compounds capable of modulating cancer-related signaling pathways, warranting deeper pharmacological investigations.

By unveiling a previously uncharted molecular pathway linking disulfiram to tumor suppression in liver cancer, this research not only expands the scientific understanding of HCC biology but also catalyzes hope for more effective, accessible, and targeted therapies in the near future.

Subject of Research: Liver cancer (hepatocellular carcinoma), RNA epigenetics, lipid metabolism, angiogenesis, drug repurposing
Article Title: Disulfiram combats hepatocellular carcinoma by modulating TRMT10C-mediated RNA methylation, enhancing c-FOS expression, and suppressing PCSK9 and CD146 to inhibit tumor growth and angiogenesis
News Publication Date: 2024
Web References: http://dx.doi.org/10.1007/s11427-024-2968-1
Image Credits: ©Science China Press
Keywords: hepatocellular carcinoma, disulfiram, TRMT10C, c-FOS, PCSK9, CD146, RNA methylation, lipid metabolism, angiogenesis, anti-cancer therapy, copper ionophore, drug repurposing

Hepatocellular carcinoma remains one of the most lethal malignancies worldwide, often marked by resistance to conventional therapies, especially in cases harboring mutations in the tumor suppressor gene p53. The p53 mutation typically confers aggressive growth and poor prognosis, making targeted interventions imperative. The recent findings presented by Li and colleagues bring forth a compelling narrative on how heat-induced growth stimulation in p53-mutant Huh-7 cells can be curtailed through biochemical modulation by Tanshinone IIA.

Tanshinone IIA, a bioactive compound isolated from the traditional medicinal herb Salvia miltiorrhiza, has been recognized for its multifarious pharmacological properties, including anti-inflammatory and antioxidant functions. However, its role in modulating cancer cell metabolism—particularly under stress conditions such as heat—had remained largely enigmatic until now. This study meticulously explores the interplay between hyperthermia and metabolic reprogramming in HCC cells, revealing how Tanshinone IIA interferes with crucial survival pathways.

The crux of the research demonstrates that heat exposure induces an atypical proliferative response in p53-mutant Huh-7 cells, a phenomenon that complicates therapy-induced hyperthermia approaches. Intriguingly, Tanshinone IIA administration was shown to impede this heat-induced growth enhancement effectively. Mechanistically, this anti-proliferative effect is attributed to the modulation of osmotic homeostasis and glycolytic flux, both pivotal in maintaining cellular viability under thermal stress.

Delving deeper, the study identifies ALDH7A1, an enzyme traditionally known for its role in aldehyde detoxification, as a critical molecular target of Tanshinone IIA. ALDH7A1 appears to orchestrate the metabolic adaptation of HCC cells to heat by regulating osmolyte balance and glucose metabolism. Targeting ALDH7A1 disrupts this adaptation, thereby sensitizing cancer cells to heat and curbing their pathological growth.

The researchers employed a battery of sophisticated molecular and cellular assays to validate these findings. Gene expression analyses revealed that Tanshinone IIA treatment downregulated key glycolytic enzymes and osmotic regulators in a dose-dependent manner. Functional assays further corroborated that inhibiting ALDH7A1 enzymatic activity mimicked the effects of Tanshinone IIA, underscoring the enzyme’s indispensability in the heat-induced growth response.

An exciting aspect of this investigation is the dual modulatory role of Tanshinone IIA—simultaneously impacting metabolic homeostasis and stress adaptation. By disrupting glycolysis, the primary energy-generating pathway in cancer cells, and perturbing osmotic balance, the compound exerts multifaceted stress that cumulatively undermines cancer cell survival. This multi-targeted effect not only enhances therapeutic efficacy but also reduces the likelihood of resistance development.

From a clinical translational perspective, this study opens new avenues for combining Tanshinone IIA with hyperthermia-based treatments. Conventional hyperthermic therapy seeks to exploit cancer cells’ vulnerability to elevated temperatures; however, the adaptive metabolic rewiring often diminishes its effectiveness. Administering Tanshinone IIA could potentiate hyperthermia by subverting these adaptive responses, offering a synergistic approach to HCC management.

Beyond its immediate implications in HCC, the identification of ALDH7A1 as a metabolic vulnerability holds transformative potential across various cancers where similar metabolic plasticity underlies resistance. The enzyme’s involvement in both detoxification and metabolic regulation links it uniquely to tumor survival under hostile conditions, making it a valuable target for future drug development.

Furthermore, this study underscores the importance of integrating metabolic and genetic insights to design precision therapies. The specificity of Tanshinone IIA’s action against p53-mutant cells signifies that mutational context profoundly influences therapeutic outcomes, advocating for molecularly tailored interventions in oncology.

The elucidation of osmotic homeostasis as a vital component of cancer cell survival under heat stress introduces an often-overlooked facet of tumor biology. Osmolytes, by regulating cell volume and ionic balance, contribute critically to the stress adaptation machinery. Therapeutic strategies aimed at disrupting this balance, as demonstrated by Tanshinone IIA’s effect, represent a novel frontier in cancer treatment.

Another notable highlight of the research is the comprehensive methodological framework encompassing molecular biology, biochemistry, and cell physiology, ensuring robust and reproducible conclusions. The convergence of these disciplines provides a holistic view of the therapeutic mechanism, enhancing confidence in the translational potential of the findings.

Intriguingly, Tanshinone IIA’s capacity to influence glycolysis intersects with the well-documented Warburg effect in cancer cells, where glycolytic metabolism persists even in oxygen-rich environments. By attenuating glycolytic enzyme expression, the compound acts as a metabolic gatekeeper, restricting the energetic currency necessary for unchecked proliferation.

This study not only advances our understanding of hepatocellular carcinoma biology but also enriches the pharmacopeia of natural compounds with high therapeutic potential. The rediscovery and repurposing of traditional medicines like Tanshinone IIA exemplify the fruitful amalgamation of ethnopharmacology and modern molecular medicine.

Looking forward, further investigations will need to validate these in vitro findings in vivo, exploring pharmacokinetics, optimal dosing, and potential side effects of Tanshinone IIA in combination with hyperthermic therapy. Moreover, elucidating the broader systemic effects and immune interactions will be critical before clinical translation.

In sum, the research presented by Li et al. marks a significant stride in cancer therapeutics, unveiling Tanshinone IIA as a potent modulator of heat-induced growth in p53-mutant HCC through a sophisticated mechanism involving ALDH7A1-mediated metabolic and osmotic regulation. This work paves the way for innovative combinatorial treatments, promising improved outcomes for patients battling hepatocellular carcinoma.

Subject of Research: Hepatocellular carcinoma (HCC), specifically targeting p53-mutant Huh-7 liver cancer cells under heat-induced growth conditions and the metabolic regulation via ALDH7A1.

Article Title: Tanshinone IIA inhibits heat-induced growth of p53-mutant Huh-7 hepatocellular carcinoma by modulating osmotic homeostasis and glycolysis through targeting ALDH7A1.

Article References:
Li, H., Ju, S., Wang, J. et al. Tanshinone IIA inhibits heat-induced growth of p53-mutant Huh-7 hepatocellular carcinoma by modulating osmotic homeostasis and glycolysis through targeting ALDH7A1. Cell Death Discov. 11, 493 (2025). https://doi.org/10.1038/s41420-025-02795-0

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02795-0

Hepatocellular carcinoma remains one of the most lethal malignancies worldwide, often diagnosed at stages too advanced for surgical intervention. Patients categorized within BCLC stage C face limited options, as systemic therapies frequently offer modest benefits. The innovative therapeutic combination explored in this study leverages the complementary mechanisms of locoregional and systemic treatments, aiming to overcome tumor resistance and improve clinical outcomes.

The clinical trial enrolled 31 patients diagnosed with advanced unresectable HCC. Initial treatment involved TACE, a minimally invasive procedure designed to deliver chemotherapy directly to liver tumors while obstructing their blood supply. This locoregional intervention was immediately followed by administration of lenvatinib, a multi-kinase inhibitor known to disrupt tumor angiogenesis and proliferation, and tislelizumab, a novel anti-PD-1 monoclonal antibody that reactivates anti-tumor immune responses.

Patients in the trial received tislelizumab intravenously every 21 days at a dose of 200 mg, while lenvatinib was administered daily at 8 or 12 mg, adjusting for patient-specific factors such as weight. The study’s primary endpoint was the objective response rate (ORR), assessed through modified Response Evaluation Criteria in Solid Tumors (mRECIST). Secondary endpoints encompassed safety evaluations, overall survival (OS), progression-free survival (PFS), time to progression (TTP), duration of response (DOR), and the exploration of biomarkers such as the systemic immune-inflammation index (SII) to predict therapeutic efficacy.

Remarkably, the triple therapy demonstrated an ORR of 74.2%, a substantial improvement compared to historical controls treated with monotherapies or dual treatment regimens. Additionally, the disease control rate (DCR) reached an impressive 87.1% per mRECIST criteria, reflecting not only tumor shrinkage but also stabilization. These outcomes suggest a synergistic effect of combining local chemoembolization with systemic immunomodulation and targeted inhibition.

Median overall survival was reported at 12.6 months, while median progression-free survival extended to 6.5 months. Notably, the median time to progression observed was 8.2 months, and the median duration of response lasted 7.3 months. These metrics indicate a meaningful extension in survival and tumor control, offering hope to patients traditionally facing dismal prognoses under current standard care.

Safety profiles were carefully monitored and remained within manageable levels. Treatment-related adverse events (TRAEs) were documented in 64.5% of patients; however, most were grade 1 or 2, indicating mild to moderate severity. Serious adverse events of grade 3 or higher occurred in 19.4% of participants, underscoring the necessity for vigilant clinical monitoring but affirming an acceptable tolerability of the regimen.

The study also explored the prognostic significance of systemic immune-inflammation index (SII), a composite marker derived from peripheral blood parameters reflecting the balance of immune and inflammatory responses. Patients presenting with lower baseline SII exhibited superior overall survival and progression-free survival, highlighting SII’s potential as a predictive biomarker to tailor personalized treatment plans and optimize outcomes.

The mechanistic rationale of this triple combination stems from each modality’s distinct but complementary action against HCC. TACE initiates localized cytotoxicity while potentially exposing tumor antigens. Lenvatinib’s anti-angiogenic effects disrupt the tumor microenvironment, thereby inhibiting vascular support essential for tumor growth. Meanwhile, tislelizumab unleashes immune-mediated tumor cell elimination by blocking the PD-1 immune checkpoint pathway, thus enhancing the host’s anti-cancer immunity.

This study represents a crucial advancement in oncologic therapeutics by integrating locoregional and systemic strategies with immune checkpoint blockade. The encouraging clinical results provide a foundation for larger-scale, randomized controlled trials that may establish this triple therapy as a new standard of care for patients with advanced HCC, particularly those ineligible for surgical resection.

The promising outcomes also underscore the importance of biomarker-driven treatment personalization. Utilizing indices like SII could refine patient selection, guide treatment intensity, and ultimately improve survival rates in a disease notorious for therapeutic resistance. Future research will aim to validate these findings, explore mechanisms underpinning therapy resistance, and develop next-generation combination therapies.

Despite the inherent challenges posed by the complex biology of hepatocellular carcinoma, this early-phase study’s results invigorate the field with hope. They emphasize the power of a multifaceted approach that exploits tumor vulnerabilities across biological domains, combining cytotoxic, anti-angiogenic, and immunotherapeutic effects in a cohesive treatment paradigm.

In conclusion, the combination of TACE, lenvatinib, and tislelizumab offers a potent therapeutic option for patients with advanced, unresectable HCC. The phase II clinical trial demonstrates not only a high objective response rate but also an acceptable safety profile, paving the way for more extensive studies and potential paradigm shifts in managing this challenging malignancy. With continued investigation, this approach could significantly improve survival and quality of life for countless patients worldwide.

ClinicalTrials.gov records identify this study under the identifier NCT05131698, reflecting its rigorous protocol and ethical oversight. As the oncology community awaits further data, this pioneering research reinforces the promise of combination therapies and precision medicine in transforming liver cancer treatment.

Subject of Research: Advanced unresectable hepatocellular carcinoma treatment through combination therapy involving TACE, lenvatinib, and tislelizumab.

Article Title: Preliminary experience of lenvatinib, tislelizumab and transcatheter arterial chemoembolization for BCLC stage C hepatocellular carcinoma: a phase II study.

Article References:
Nong, X., Yao, Y., Xie, J. et al. Preliminary experience of lenvatinib, tislelizumab and transcatheter arterial chemoembolization for BCLC stage C hepatocellular carcinoma: a phase II study. BMC Cancer 25, 1631 (2025). https://doi.org/10.1186/s12885-025-15016-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-15016-9

This ground-breaking research centers on the metabolic enzyme ATP citrate lyase (ACLY), a key catalyst in the biochemical conversion of glucose to lipid molecules within liver cells. Tumor cells notoriously hijack this metabolic pathway, exploiting fat synthesis to fuel their unchecked growth and survival. The team at McMaster engineered a pharmacological agent — EVT0185 — designed to selectively inhibit ACLY activity within hepatic tissues. This targeted approach interrupts the tumor’s metabolic lifeline, substantially stunting its progression while sparing other organs from systemic side effects.

Strikingly, the treatment did more than halt tumor growth; it revitalized the immune environment within the liver. Conventional cancer immunotherapy paradigms emphasize the pivotal role of cytotoxic T lymphocytes (CTLs) in recognizing and eradicating cancer cells. However, the McMaster study revealed a surprising actor in the anti-tumoral immune orchestra: B cells. These antibody-producing lymphocytes, long overshadowed by T cells in cancer research, emerged as critical mediators of tumor clearance following ACLY inhibition.

The enhanced immunogenicity of liver tumors post-treatment was unexpected and profound. B cells infiltrated the tumor microenvironment in greater numbers, orchestrating complex immune responses that synergized with other immune components. This novel insight challenges the prevailing dogma that T cells are the sole immune warriors in solid tumors and suggests that modulating cancer metabolism can selectively amplify anti-tumor B cell activity.

At a mechanistic level, ACLY inhibition curtails the intracellular synthesis of acetyl-CoA derived from citrate, disrupting lipid biogenesis critical for membrane formation and energy storage in tumor cells. This lipid deprivation likely induces metabolic stress, exposing tumor-associated antigens and rendering cancer cells more visible to immune surveillance. Additionally, altering tumor metabolism may reshape cytokine profiles in the microenvironment, thereby recruiting and activating B cells more effectively.

Fatty liver disease, medically termed metabolic dysfunction–associated steatotic liver disease (MASLD), affects nearly eight million individuals in Canada alone, with a significant subset progressing to a more severe inflammatory state known as metabolic dysfunction-associated steatohepatitis (MASH). These patients bear a disproportionately high risk of developing aggressive liver cancers such as HCC, which historically has seen dismal survival rates—less than 20% of patients survive beyond five years. The introduction of EVT0185 and its ACLY-targeted mechanism offers a promising avenue to alter this grim prognosis.

In preclinical trials, murine models simulating human MASH coupled with HCC were treated with EVT0185, resulting in a marked reduction in both tumor burden and growth rate. Importantly, treated tumors exhibited heightened susceptibility to immune-mediated destruction, primarily through B cell engagement rather than the anticipated cytotoxic T cell pathways. This discovery opens new investigative directions into B cell biology within cancer and may inspire innovative immunotherapies designed to harness these cells’ full potential.

While promising, the research team acknowledges the complexity inherent in translating these findings to clinical practice. Future studies must unravel the precise immunological cascades initiated by ACLY inhibition, determine the safety and efficacy of EVT0185 in human subjects, and explore whether similar strategies can be effective across diverse malignancies with metabolic dependencies. Moreover, understanding how B cells communicate with other immune subsets in the tumor microenvironment will be crucial in designing comprehensive treatment protocols.

This investigation exemplifies the power of targeting cancer metabolism not merely as a metabolic reprogramming stance but as a strategic lever to remodel immune responses. By switching off a vital metabolic enzyme, researchers have demonstrated a capacity to “unmask” tumors and enlist underappreciated immune players in the eradication effort, thereby expanding the therapeutic landscape beyond conventional cytotoxic and checkpoint inhibitor approaches.

The study was made possible through funding from the Canadian Institutes of Health Research Foundation Grant and collaborative investment from Espervita Therapeutics, underscoring the increasing importance of academia-industry partnerships in advancing translational medicine. Notably, several authors maintain shareholder positions within Espervita, highlighting a close integration of research innovation and biotechnological development.

As this research paves the way for next-generation liver cancer therapies, it also sparks a broader imperative to revisit the metabolic underpinnings across other cancers. Metabolic enzymes like ACLY may constitute a new class of druggable targets capable of simultaneously disabling tumor nutrition and invigorating immune defenses. Such dual-action therapeutics could revolutionize oncological treatment paradigms, addressing resistance mechanisms and poor immunogenicity that have long hampered success.

In summary, the McMaster University and Espervita Therapeutics collaboration reveals a transformative approach to liver cancer treatment by inhibiting ACLY, the pivotal enzyme linking carbohydrate metabolism to fat synthesis. This intervention disrupts tumor metabolic homeostasis, triggers an unexpected B cell-driven immune response, and reduces tumor viability in preclinical models. While human trials are the next critical step, these findings significantly deepen our understanding of cancer immunometabolism and open promising avenues for combating one of the world’s deadliest cancers.

Subject of Research: Liver cancer metabolism and immune system interaction focusing on ACLY enzyme inhibition and B cell-mediated tumor immunity
Article Title: Inhibiting ACLY enhances tumour immunogenicity and resolves MASH-HCC
News Publication Date: 30-Jul-2025
Web References: 10.1038/s41586-025-09297-0
Keywords: Cancer, Liver cancer, Metabolism, Immunotherapy, B cells, ATP citrate lyase, Fatty liver disease, MASLD, MASH, Tumor microenvironment, Hepatocellular carcinoma, Immune metabolism

Hepatocellular carcinoma remains one of the most prevalent malignancies worldwide and carries a notoriously high recurrence rate following surgical resection. Such recurrences often present as unresectable lesions, demanding alternative therapeutic approaches. Despite advances in loco-regional therapies, no standardized treatment regimen currently exists for managing recurrent unresectable HCC, highlighting an urgent unmet clinical need.

The study, published in BMC Cancer, retrospectively analyzed clinical data from 83 patients diagnosed with recurrent unresectable HCC after initial surgery. The patients were stratified into three distinct treatment cohorts based on their regimens: a group receiving HAIC combined with TKIs and PD-1 inhibitors (HTP), a second group treated with TACE in combination with TKIs and PD-1 inhibitors (TTP), and a third control group undergoing TACE alone. This design enabled a robust comparative assessment of treatment efficacy and safety among cutting-edge combination therapies versus standard intervention.

HAIC and TACE are both hepatic artery-targeted therapies aimed at delivering chemotherapeutic agents directly to liver tumors, thereby maximizing local antitumor activity while limiting systemic toxicity. Combining these modalities with TKIs, which inhibit angiogenesis and tumor proliferation pathways, alongside PD-1 inhibitors that unleash anti-tumor immune responses, represents an innovative multimodal approach to tackle tumor progression on multiple fronts simultaneously.

The primary endpoint assessed was progression-free survival (PFS), a critical measure reflecting the duration during which patients remained free from disease advancement. Results revealed a marked improvement in median PFS among patients receiving combination therapy. Specifically, the HTP group demonstrated a median PFS of 13.7 months, substantially longer than the 9.2 months observed in the TTP group and dramatically exceeding the 2.5 months recorded for those treated with TACE alone. These findings underscore the additive benefit of incorporating both TKIs and PD-1 inhibitors alongside hepatic arterial infusion strategies.

Beyond survival metrics, tumor response was meticulously evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST), a standard for assessing therapeutic efficacy in HCC that accounts for changes in viable tumor tissue. The disease control rate (DCR), encompassing complete response (CR), partial response, and stable disease, was significantly higher in the HTP cohort at 89.7%, compared to 75.0% in the TTP group and only 50.0% with TACE monotherapy. The objective response rate (ORR), indicative of measurable tumor shrinkage, also favored combination regimens, reaching 44.8% and 35% in the HTP and TTP groups respectively, versus a mere 14.7% in the control group.

Remarkably, the incidence of complete response was restricted to the HTP group, with 17.2% of patients achieving this outcome. This contrasts starkly with a complete response rate of zero in both the TTP and TACE alone arms. Such results suggest that HAIC, when synergized with TKIs and PD-1 checkpoint blockade, may elicit profound antitumor effects potentially capable of eradicating clinically evident disease in a subset of patients.

Safety profiles across treatment arms were carefully monitored, revealing no occurrences of serious adverse reactions within the HTP and TTP groups. This highlights the tolerability of these combination regimens, which is pivotal considering the typically compromised hepatic reserve and overall frailty of advanced HCC patients. The absence of severe toxicity supports the feasibility of integrating immunotherapy and targeted agents with locoregional chemotherapy in clinical practice.

Mechanistically, the therapeutic synergy observed likely stems from complementary modes of action. TKIs suppress tumor angiogenesis and cellular proliferation, thereby restricting nutrient supply and direct tumor growth. PD-1 inhibitors enhance the host immune system’s capacity to recognize and destroy cancer cells by preventing immune checkpoint-mediated T cell exhaustion. Concurrently, HAIC and TACE deliver localized cytotoxic chemotherapy that induces tumor necrosis. This concerted attack disrupts the tumor microenvironment, potentially overcoming resistance mechanisms seen with monotherapy.

This study’s implications extend far beyond survival statistics. It emphasizes the evolving landscape of HCC treatment, where integrating systemic immunomodulation and targeted therapy with traditional intra-arterial chemotherapy heralds a new era of personalized oncology. Identifying patients most likely to benefit from such regimens remains an ongoing challenge, necessitating further biomarker-driven investigations.

Despite its retrospective design and relatively modest sample size, the research offers compelling evidence warranting prospective, randomized clinical trials to validate these findings. The ability to induce complete responses in previously refractory recurrent HCC patients could translate into durable remissions and improved overall survival, transforming standard care paradigms.

In summary, the combination of TKIs and PD-1 inhibitors with HAIC or TACE demonstrates superior efficacy and safety compared to TACE alone in treating recurrent unresectable hepatocellular carcinoma. Particularly, HAIC combined with these systemic agents achieves the highest complete response rates, shedding light on promising therapeutic avenues. As liver cancer continues to pose formidable clinical challenges, these findings pave the way toward more effective, multimodal treatment strategies that improve patient outcomes and quality of life.

Future research should aim to elucidate the molecular underpinnings driving response heterogeneity and resistance, optimize dosing schedules, and evaluate long-term survivorship benefits. Moreover, integrating advanced imaging modalities and liquid biopsy approaches may facilitate early detection of treatment response and recurrence, further refining clinical decision-making. Ultimately, multidisciplinary collaboration will be key to translating these scientific insights into routine clinical application.

The study stands as a testament to the rapidly advancing frontier of oncological therapeutics, underscoring the power of combining precision medicine, immunotherapy, and locoregional interventions. As these innovations converge, they offer renewed optimism for patients confronting the formidable challenge of recurrent unresectable hepatocellular carcinoma.

Subject of Research: Treatment efficacy and safety of tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors combined with hepatic arterial infusion chemotherapy/transarterial chemoembolization for recurrent unresectable hepatocellular carcinoma.

Article Title: The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein-1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma.

Article References:
Deng, W., Xie, J., Wang, T. et al. The safety and efficacy of tyrosine kinase inhibitors and programmed cell death protein- 1 inhibitors combined with HAIC/TACE in the treatment of recurrent unresectable hepatocellular carcinoma. BMC Cancer 25, 779 (2025). https://doi.org/10.1186/s12885-025-14185-x

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14185-x